ArticleBrain communications2026
Enhanced sensitivity to plasma p-tau217 with proper names recall in the preclinical Alzheimer's cognitive composite.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A pivotal debate in Alzheimer's disease (AD) revolves around the clinical utility of a purely biomarker-based diagnostic framework, making it imperative to identify early functional signs that are both clinically meaningful and sensitive to biological biomarkers in the preclinical stages. While the development of the Preclinical Alzheimer's Cognitive Composite (PACC) addresses this need, its lack of language-specific markers might limit its sensitivity, given that language deficits are among the earliest manifestations of AD. To address this limitation, we developed PACC variants incorporating proper names delayed recall, a novel lexical-semantic marker robustly linked to PET and CSF biomarkers. We analysed 824 dementia-free participants (mean age ≈ 62 at baseline) from the Wisconsin Registry for Alzheimer's Prevention, stratifying them by plasma phosphorylated tau 217 (p-tau217) levels (using established amyloid PET positivity cut-offs: negative [<0.40 pg/mL;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.